Peer-reviewed scientific publication highlighting CombiCult® technology demonstrates power of massively parallel stem cell differentiation

Plasticell Limited announced today the publication of peer-reviewed scientific research that demonstrates how the company’s proprietary ‘Combinatorial Cell Culture™‘ (CombiCult®) technology allows scientists to perform and compare 10,000 embryonic stem cell differentiation experiments in parallel. The individual experiments would have required around 200 years to complete back-to-back. The paper entitled ‘Directed differentiation of embryonic stem cells using a bead-based combinatorial [...]

2021-05-28T22:26:50+01:00September 25th, 2014|Press Releases|

Plasticell spin-out, Progenitor Labs, named a Finalist for the 2014 Red Herring Top 100 Europe Award

Progenitor Labs, the biotech company developing small molecule drugs to regenerate organs of the body, announced today it has been selected a Red Herring Top 100 Europe Finalist, a prestigious list honoring the year’s most promising private technology ventures from the European business region. The Red Herring editorial team selected the most innovative companies from a pool of hundreds in [...]

2021-06-01T11:03:05+01:00March 25th, 2014|Press Releases|

Plasticell signs deal with JCR Pharmaceuticals to use CombiCult® stem cell technology in Japan

Plasticell, the biotechnology company specializing in stem cell differentiation, has today announced that it has signed a collaboration agreement with JCR Pharmaceuticals Co., Ltd. of Ashiya, Hyogo Pref., Japan, to discover custom stem cell culture media using its award-winning combinatorial stem cell technology, CombiCult®. Under the terms of the agreement, Plasticell will use its stem cell expertise to work with [...]

2021-06-01T11:05:18+01:00February 24th, 2014|Press Releases|

Additional family of CombiCult® patents granted in USA, Europe, Australia and Singapore

Plasticell, the biotechnology company developing regenerative drugs using high throughput stem cell technologies, has announced that a further family of patents, offering additional protection of its proprietary cell culture technology, Combinatorial Cell Culture™ (CombiCult®), have been granted by the US Patent Office, European Patent Office, Australian Patent Office and Intellectual Property Office of Singapore. The newly granted patents cover the [...]

2021-06-01T11:06:56+01:00November 11th, 2013|Press Releases|

Plasticell and Progenitor Labs seed cell therapy activities at the Stevenage Bioscience Catalyst open innovation campus

Stevenage Bioscience Catalyst (SBC), the UK’s first open innovation bioscience campus, is pleased to welcome regenerative medicine companies Plasticell Ltd and Progenitor Labs as tenants. Progenitor Labs is a drug discovery spin-off from Plasticell and recently received £4m in funding from SR One, the corporate venture arm of GlaxoSmithKline (GSK). Cell therapy and regenerative medicine is a focus of SBC’s [...]

2021-06-01T11:08:53+01:00June 10th, 2013|Press Releases|

Licenced from Plasticell, EMD Millipore Launches OsteoMAX-XF™, a Fully-defined, Xeno-free Mesenchymal Stem Cell Osteogenic Differentiation Medium

EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, and Plasticell of London, UK, today announced the availability of OsteoMAX-XF™, the first fully defined, xeno-free human mesenchymal stem cell differentiation medium for the differentiation of mesenchymal stem cells into osteocytes. Mineralization can be detected in less than one week, whereas competing products that contain serum require approximately [...]

2021-06-01T11:10:22+01:00May 9th, 2013|Press Releases|

Plasticell’s regenerative medicine drug discovery spin-off Progenitor Labs secures £4m financing from GSK’s corporate venture fund SR One

Investment from SR One, GlaxoSmithKline’s Corporate Venture Fund, will fund company’s programme to discover small molecule drugs that regenerate specific tissues of the body. Progenitor Labs Ltd (Progenitor) has announced that it has raised £4 million ($5.8million) in seed financing from SR One’s UK Fund. Progenitor is a pioneering regenerative medicine company that develops drugs to regenerate specific tissues of [...]

2021-06-01T11:11:56+01:00March 11th, 2013|Press Releases|

Plasticell and EMD Millipore complete licensing deal to distribute fully defined, xeno-free mesenchymal stem cell differentiation media

Plasticell, the UK stem cell differentiation specialist has licensed EMD Millipore, the Life Science Division of Merck KGaA, to distribute a superior, single-application osteogenic medium discovered using the award winning, massively parallel combinatorial screening system, CombiCult®. The osteogenic medium is serum- and xeno- free, more consistent and more potent than currently available formulations. Under the terms of the contract, [...]

2016-12-09T12:43:57+00:00August 14th, 2012|Press Releases|

Plasticell and Veritas announce an exclusive distribution agreement in Japan

Plasticell, the biotechnology company specialising in high throughput technologies for directed stem cell differentiation, has today announced that it has engaged Veritas Corporation of Tokyo as the exclusive distributor for all of its services and products, including CombiCult®, in Japan. CombiCult® breaks the major bottleneck in stem cell research and development programmes – the discovery of optimised stem cell differentiation [...]

2021-06-01T11:48:03+01:00June 14th, 2012|Press Releases|

Plasticell announces grant of fundamental CombiCult® patents in USA and Japan

Plasticell, the biotechnology company specialising in high throughput technologies for directed stem cell differentiation, today announced that patents for its combinatorial cell culture platform technology, CombiCult™, have been granted in the USA and Japan. Patents covering CombiCult™ have now been issued in Europe, USA, Japan, Australia and Singapore. CombiCult™ breaks the major bottleneck in stem cell research and development programmes [...]

2021-06-01T11:44:33+01:00February 13th, 2012|Press Releases|